Marco Galluzzo

Qualifica
RICERCATORI A CONTRATTO
Fonte dei dati: Archivio della Ricerca http://art.torvergata.it
  1. Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., et al. (2021). Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. DERMATOLOGY AND THERAPY, 11(1), 235-252. Dettagli
  2. Morelli, M., Galluzzo, M., Madonna, S., Scarponi, C., Scaglione, G.L., Galluccio, T., et al. (2021). HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(2), 259-270 [10.1080/14712598.2021.1862082]. Dettagli
  3. Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., et al. (2021). Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(2), 271-277 [10.1080/14712598.2021.1853698]. Dettagli
  4. Galluzzo, M., Talamonti, M., Manfreda, V., Silvaggio, D., Tartaglia, C., Roberto, D., et al. (2020). Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. EXPERT OPINION ON BIOLOGICAL THERAPY [10.1080/14712598.2021.1849131]. Dettagli
  5. Talamonti, M., & Galluzzo, M. (2020). Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information. ANNALS OF TRANSLATIONAL MEDICINE, 8(15), 971-971. Dettagli
  6. Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., et al. (2020). Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. Dettagli
  7. Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C.g., et al. (2020). Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. JOURNAL OF CLINICAL MEDICINE, 9(7), 2170. Dettagli
  8. Talamonti, M., Tofani, L., Bianchi, L., & Galluzzo, M. (2020). Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?. ARCHIVES OF DERMATOLOGICAL RESEARCH. Dettagli
  9. Mazzilli, S., Lanna, C., Chiaramonte, C., Cesaroni, G.M., Zangrilli, A., Palumbo, V., et al. (2020). Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. JOURNAL OF DERMATOLOGY. Dettagli
  10. Caldarola, G., Pirro, F., Di Stefani, A., Talamonti, M., Galluzzo, M., D'Adamio, S., et al. (2020). Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(6), 665-672 [10.1080/14712598.2020.1727439]. Dettagli
  11. Campione, E., Lanna, C., Diluvio, L., Cannizzaro, M.V., Grelli, S., Galluzzo, M., et al. (2020). Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. CELL CYCLE, 19(3), 257-267 [10.1080/15384101.2019.1707455]. Dettagli
  12. D'Adamio, S., Massaro, A., Biocca, S., Bianchi, L., Talamonti, M., & Galluzzo, M. (2020). A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 45(6), 809-810. Dettagli
  13. Galluzzo, M., D'Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., & Talamonti, M. (2020). In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(2), 173-182 [10.1080/14712598.2020.1708897]. Dettagli
  14. Galluzzo, M., D'Adamio, S., Silvaggio, D., Lombardo, P., Massaro, A., Egan, C.G., et al. (2020). Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(1), 95-104 [10.1080/14712598.2020.1684472]. Dettagli
  15. Galluzzo, M., Tofani, L., Bianchi, L., & Talamonti, M. (2020). Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. EXPERT OPINION ON BIOLOGICAL THERAPY, 20(8), 829-830. Dettagli
  16. van Vugt, L.J., van den Reek, J., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., et al. (2020). Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 34(1), 112-118. Dettagli
  17. D'Adamio, S., Silvaggio, D., Massaro, A., Lombardo, P., Bianchi, L., Talamonti, M., et al. (2019). Pharmacotherapeutic management of psoriasis in adolescents and children. EXPERT OPINION ON PHARMACOTHERAPY, 20(14), 1777-1785 [10.1080/14656566.2019.1636032]. Dettagli
  18. Mazzilli, S., Giunta, A., Galluzzo, M., Garofalo, V., Campione, E., Di Prete, M., et al. (2019). Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA. Dettagli
  19. Talamonti, M., D'Adamio, S., Galluccio, T., Andreani, M., Pastorino, R., Egan, C.g., et al. (2019). High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY [10.1111/jdv.15659]. Dettagli
  20. Galluzzo, M., D'Adamio, S., Teoli, M., Bianchi, L., & Talamonti, M. (2019). Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. DERMATOLOGIC THERAPY, e12899 [10.1111/dth.12899]. Dettagli
  21. Galluzzo, M., D'Adamio, S., Chimenti, M.s., Teoli, M., Bianchi, L., & Talamonti, M. (2019). Successful treatment of psoriatic crumbly nails with ustekinumab. DERMATOLOGIC THERAPY, e12914 [10.1111/dth.12914]. Dettagli
  22. Chimenti, M.S., Fonti, G.L., Conigliaro, P., Hitaj, J., Triggianese, P., Teoli, M., et al. (2019). Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. MEDICINE, 98(4), e13955. Dettagli
  23. D'Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., Talamonti, M., & Galluzzo, M. (2019). The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 18(11), 1031-1041 [10.1080/14740338.2019.1663168]. Dettagli
  24. Galluzzo, M., D'Adamio, S., Bianchi, L., & Talamonti, M. (2019). Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 30(1), 40-44 [10.1080/09546634.2018.1468066]. Dettagli
  25. Galluzzo, M., D'Adamio, S., Massaro, A., Piccolo, A., Bianchi, L., & Talamonti, M. (2019). Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 12, 311-321 [10.2147/CCID.S165605]. Dettagli
  26. Lanna, C., Mancini, M., Gaziano, R., Cannizzaro, M.v., Galluzzo, M., Talamonti, M., et al. (2019). Skin immunity and its dysregulation in psoriasis. CELL CYCLE, 18(20), 2581-2589 [10.1080/15384101.2019.1653099]. Dettagli
  27. Papini, M., Cusano, F., Romanelli, M., Burlando, M., Stinco, G., Girolomoni, G., et al. (2019). Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study. BRITISH JOURNAL OF DERMATOLOGY, 181(2), 413-414 [10.1111/bjd.18013]. Dettagli
  28. Puviani, M., Galluzzo, M., Talamonti, M., Mazzilli, S., Campione, E., Bianchi, L., et al. (2019). Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. INTERNATIONAL JOURNAL OF STD & AIDS, 30(2), 131-136 [10.1177/0956462418797874]. Dettagli
  29. Rossi, A., Muscianese, M., Piraccini, B.M., Starace, M., Carlesimo, M., Mandel, V.D., et al. (2019). Italian guidelines in diagnosis and treatment of alopecia areata. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 154(6), 609-623. Dettagli
  30. Signa, S., Campione, E., Rusmini, M., Chiesa, S., Grossi, A., Omenetti, A., et al. (2019). Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL, 17(1), 38. Dettagli
  31. Galluzzo, M., D'Adamio, S., Campione, E., Bianchi, L., & Talamonti, M. (2018). Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-018-0354-8]. Dettagli
  32. Chimenti, M.S., Ortolan, A., Lorenzin, M., Triggianese, P., Talamonti, M., Costa, L., et al. (2018). Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. CLINICAL RHEUMATOLOGY, 37(2), 397-405. Dettagli
  33. Costanzo, A., Bianchi, L., Flori, M., Malara, G., Stingeni, L., Bartezaghi, M., et al. (2018). Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. BRITISH JOURNAL OF DERMATOLOGY, 179(5), 1072-1080. Dettagli
  34. Galluzzo, M., D'Adamio, S., Bianchi, L., & Talamonti, M. (2018). Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(2), 197-206 [10.1080/17425255.2018.1420162]. Dettagli
  35. Galluzzo, M., D'Adamio, S., Campione, E., Bianchi, L., & Talamonti, M. (2018). A safety evaluation of guselkumab for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 17(7), 741-751 [10.1080/14740338.2018.1488963]. Dettagli
  36. Galluzzo, M., D'Adamio, S., Campione, E., Mazzilli, S., Bianchi, L., & Talamonti, M. (2018). A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 29, 17-20 [10.1080/09546634.2018.1524818]. Dettagli
  37. Galluzzo, M., D’Adamio, S., Pastorino, R., Angela Andreoli, A., Servoli, S., Bianchi, L., et al. (2018). Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(3), 229-235 [10.1080/14712598.2018.1419183]. Dettagli
  38. Galluzzo, M., Talamonti, M., De Simone, C., D'Adamio, S., Moretta, G., Tambone, S., et al. (2018). Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(7), 727-735 [10.1080/14712598.2018.1481503]. Dettagli
  39. Talamonti, M., Galluzzo, M., Bernardini, N., Caldarola, G., Persechino, S., Cantoresi, F., et al. (2018). Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 32(10), 1737-1744. Dettagli
  40. Talamonti, M., Galluzzo, M., Servoli, S., D'Adamio, S., & Bianchi, L. (2017). Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. DERMATOLOGY, 232(6), 648-654 [10.1159/000453661]. Dettagli
  41. D'Adamio, S., Talamonti, M., Bianchi, L., & Galluzzo, M. (2017). Photo-recall cutaneous reaction to gemcitabine. ARCHIVE OF CLINICAL CASES, 4(4), 191-194 [10.22551/2017.17.0404.10113]. Dettagli
  42. Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2017). Tildrakizumab for treating psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 17(5), 645-657 [10.1080/14712598.2017.1304537]. Dettagli
  43. Galluzzo, M., Talamonti, M., D'Adamio, S., & Bianchi, L. (2017). Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(6), 679-691 [10.1080/17425255.2017.1325874]. Dettagli
  44. Galluzzo, M., Talamonti, M., Perino, F., Servoli, S., Giordano, D., Chimenti, S., et al. (2017). Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT, 28(4), 299-303. Dettagli
  45. Talamonti, M., D'Adamio, S., Bianchi, L., & Galluzzo, M. (2017). The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. MOLECULAR DIAGNOSIS & THERAPY [10.1007/s40291-017-0274-z]. Dettagli
  46. Talamonti, M., Galluzzo, M., Zangrilli, A., Papoutsaki, M., Egan, C., Bavetta, M., et al. (2017). HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. MOLECULAR DIAGNOSIS & THERAPY, 21(3), 295-301 [10.1007/s40291-017-0261-4]. Dettagli
  47. Talamonti, M., Galluzzo, M., van den Reek, J., de Jong, E., Lambert, J., Malagoli, P., et al. (2017). Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. BRITISH JOURNAL OF DERMATOLOGY, 177(2), 489-496 [10.1111/bjd.15387]. Dettagli
  48. Ventura, A., Mazzeo, M., Gaziano, R., Galluzzo, M., Bianchi, L., & Campione, E. (2017). New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. DRUG DESIGN, DEVELOPMENT AND THERAPY, 11, 2527-2535 [10.2147/DDDT.S136986]. Dettagli
  49. Galluzzo, M., Andreani, M., Testi, M., Chimenti, S., & Talamonti, M. (2016). HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. MOLECULAR DIAGNOSIS & THERAPY, 20(3), 227-230. Dettagli
  50. Galluzzo, M., Boca, A.N., Botti, E., Potenza, C., Malara, G., Malagoli, P., et al. (2016). IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. DERMATOLOGY, 232(2), 230-236. Dettagli
  51. Galluzzo, M., D'Adamio, S., BIANCHI, L., & Talamonti, M. (2016). Brodalumab for the treatment of psoriasis. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 12(12), 1255-1271 [10.1080/1744666X.2016.1246957]. Dettagli
  52. Galluzzo, M., D'Adamio, S., Servoli, S., Bianchi, L., Chimenti, S., & Talamonti, M. (2016). Tofacitinib for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 17(10), 1421-1433 [10.1080/14656566.2016.1195812]. Dettagli
  53. Talamonti, M., Galluzzo, M., Chimenti, S., & Costanzo, A. (2016). Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis. Paper presented at Annual meeting of American Academy of Dermatology, 74th. Dettagli
  54. Talamonti, M., Galluzzo, M., Chimenti, S., & Costanzo, A. (2016). HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(2), 374-375. Dettagli
  55. Chimenti, M.S., Talamonti, M., Novelli, L., Teoli, M., Galluzzo, M., Triggianese, P., et al. (2015). Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 9(3), 71-75 [10.3315/jdcr.2015.1207]. Dettagli
  56. Galluzzo, M., Talamonti, M., Di Stefani, A., & Chimenti, S. (2015). Linear psoriasis following the typical distribution of the sciatic nerve. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 9, 6-11 [10.3315/jdcr.2015.1189]. Dettagli
  57. Talamonti, M., Galluzzo, M., Botti, E., Costanzo, A., & Chimenti, S. (2015). HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients. Paper presented at ANNUAL MEETING OF AmERICAN AcadEMY OF DermatolOGY. Dettagli
  58. Talamonti, M., Galluzzo, M., Bianchi, L., Boca, A.N., Costanzo, A., & Chimenti, S. (2014). What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice. DERMATOLOGY, 229(4), 324-332 [10.1159/000365077]. Dettagli
  59. Talamonti, M., Galluzzo, M., Botti, E., Chimenti, S., & Costanzo, A. (2014). Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment. Paper presented at 7thInternational Congress of Psoriasis: from Gene to Clinic The Queen Elizabeth II Conference Centre, London, U.K. 11th-13th December 2014. Dettagli
  60. Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., et al. (2013). Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. BRITISH JOURNAL OF DERMATOLOGY, 169(2), 458-463. Dettagli
  61. Boca, A., Talamonti, M., Galluzzo, M., Botti, E., Buzoianu, A., & Costanzo., A. (2013). Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom. Paper presented at 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom. Dettagli
  62. Boca, A.N., Talamonti, M., Galluzzo, M., Botti, E., Buzoianu, A.D., & Costanzo, A. (2013). Genetic variations in IL6 and IL12B as protective markers for psoriasis. Paper presented at International Investigative Dermatology 8-11 May 2013, Edinburgh. Dettagli
  63. Boca, A.N., Talamonti, M., Galluzzo, M., Botti, E., Vesa, T.C., Chimenti, S., et al. (2013). Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. IMMUNOLOGY LETTERS, 156(1-2), 127-131. Dettagli
  64. Di Stefani, A., Galluzzo, M., Talamonti, M., Chiricozzi, A., Costanzo, A., & Chimenti, S. (2013). Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. JOURNAL OF DERMATOLOGICAL CASE REPORTS, 7(1), 5-9 [10.3315/jdcr.2013.1127]. Dettagli
  65. Saraceno, R., Talamonti, M., Galluzzo, M., Chiricozzi, A., Costanzo, A., & Chimenti, S. (2013). Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases. CASE REPORTS IN DERMATOLOGY, 5(3), 254-258. Dettagli
  66. Talamonti, M., Galluzzo, M., Botti, E., Pavlidis, A., Spallone, G., Chimenti, S., et al. (2013). Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients. CLINICAL DRUG INVESTIGATION, 33(SUPPL.2). Dettagli
  67. Botti, E., Talamonti, M., Spallone, G., Galluzzo, M., Bavetta, M., Teoli, M., et al. (2012). Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis. Paper presented at Abstracts of the 42nd Annual ESDR (European Society for Dermatological Research) Meeting. September 7-10, 2012. Venice, Italy. Dettagli
  68. Talamonti, M., Galluzzo, M., Chiricozzi, A., Teoli, M., Bavetta, M., Costanzo, A., et al. (2012). Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome. JOURNAL OF DRUGS IN DERMATOLOGY, 11(8), 1000-1002. Dettagli
  69. Talamonti, M., Galluzzo, M., Teoli, M., Bavetta, M., Chimenti, S., & Costanzo, A. (2011). Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis. Paper presented at Psoriasis: from Gene to Clinic 6th International Congress, 1-3 December 2011. Dettagli